Onyx Pharmaceuticals Inc. (NASDAQ:ONXX) has rejected a bid of $120 per share from Amgen Inc. (NASDAQ:AMGN), but most buysiders who spoke with BioCentury think it is only a matter of time until Onyx is acquired. The list of possible acquirers is long